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Abstract 
In order to better understand choice behaviour, econometric models need to be able to reflect the 
complexity of decisions that individuals routinely face. We investigate the role of choice complexity 
in modelling medical decision-making in the case of a doctor choosing which specific contraceptive 
products to discuss with their patient before ultimately making a recommendation. Clinical vignettes 
describing patients, developed using stated preference methods, are presented to a sample of 
Australian general practitioners. An econometric model is developed that captures two salient 
sources of complexity. The first is associated with patients with particular combinations of clinical 
and demographic attributes that induce uncertainty around what product to recommend while the 
second captures variation in the ability of doctors to find appropriate patient-product matches. We 
are especially interested in the tendencies of doctors to discuss long-acting reversible contraception 
(LARC) in order to determine whether part of the explanation for the relatively low uptake of LARC in 
Australia is reluctance on the part of some doctors to even discuss these products. 
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1. Introduction  
Individuals routinely face complex decisions and the source of complexity can derive from different 
aspects of the choice process. There may be a large choice set (Frank and Lamiraud, 2009); 
alternatives in the choice set may be difficult to evaluate and compare (Sándor and Franses, 2009); 
the choice context may be unfamiliar (Swait and Adamowicz, 2001). In such situations, decisions are 
often made with the assistance of a better informed expert. Water heaters are products that are 
purchased infrequently and often with some urgency and so plumbers routinely provide advice to 
consumers on the type of water heater to install (Bartels et al. 2006.) Financial advisors are one 
source of information that has the potential to compensate for poor financial literacy that is a likely 
cause of households making suboptimal decisions in complex financial choices such as retirement 
portfolios (Bateman et al. 2014). Our primary objective is to provide insights into medical decision-
making in the case of doctors advising patients on the choice of prescribed contraceptive products. 
 
Interactions between a decision maker and an expert can be characterized by an initial discussion 
stage where the expert narrows the choice set and possibly provides a recommendation as a 
precursor to the individual making the final choice. Decisions about prescribed contraception fit this 
stylized version of an individual-expert interaction. In the first stage of a consultation between a 
woman and her doctor, the doctor will be aware of a wide range of available contraceptive products 
and faces the task of matching appropriate products to the particular patient characterized by such 
attributes as their medical history, fertility plans and preferences. This process is likely to lead to a 
narrowing of the choice set that may be further restricted by costs faced by the doctor such as the 
time available during a regular consultation. Borrowing from a terminology used extensively in 
marketing this resultant subset of possible products that the doctor ultimately chooses to discuss 
with the patient is called a consideration set; see for example Roberts and Lattin (1991). 
 
Our focus is this discussion stage of a clinical encounter where the doctor decides on the 
consideration set. While the doctor is an expert, elements of complexity are likely to remain. Heiner 
(1983) and de Palma et al. (1994) emphasize the likely variation in the ability of decision-makers to 
evaluate alternatives. There will be differences in the expertise of doctors and their familiarity with 
reproductive health. Moreover, certain combinations of patient characteristics are likely to induce a 
level of complexity that increases the cognitive burden of matching contraceptive products to 
particular women. Frank and Zeckhauser (2007) suggest that such complexity is just one of the 
forces acting on primary care doctors making them less likely to make “custom made” choices and 
instead more likely to revert to “ready-to-wear” or norm-based choices.  
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Such discussions of complexity lead naturally to heteroskedastic choice models (Mazzota and 
Opaluch, 1995, Swait and Adamowicz, 2001, Sándor and Franses, 2009). Here the GMNL of Fiebig et 
al. (2010) provides the econometric framework for our analysis. GMNL explicitly allows for scale 
heterogeneity (equivalently individual level heteroskedasticity) that accommodates variation in the 
ability of the doctor and/or their tendency to revert to practice norms. This form of heterogeneity is 
also allowed to interact with patient complexity captured through a heteroskedastic random 
coefficient specification.  
 
Our focus on contraceptive choice is particularly timely because the range of contraceptive products 
available has expanded rapidly making it more challenging for women to understand the choices 
available and the trade-offs they present, and more challenging for doctors to provide 
comprehensive information to assist women in making a fully informed contraceptive choice. The 
issue of willingness to embrace new products is especially relevant given increasing support for the 
greater use of more effective longer acting reversible contraceptive (LARC) methods in order to 
reduce unintended pregnancies and abortion rates; see for example Armstrong and Donaldson 
(2005) and American College of Obstetricians and Gynecologists Committee on Gynecologic Practice 
(2009). LARC methods are contraceptives that are administered less frequently than monthly and 
include hormonal implants, intrauterine contraception (IUC), both hormonal and copper-bearing, 
and contraceptive injections. 
 
Black et al. (2013) note that despite having relatively high rates of unintended pregnancies and 
abortions, Australia has relatively low uptake of LARC methods. In a survey of Australian women, 
32% of first pregnancies were reported as unplanned and 29% were unwanted (Weisberg et al. 
2008). Eeckhaut et al. (2014) provide a cross-country comparison of the use of LARC methods and 
report rates of use in Australia (7%) that are lower than in the US (10%) and much lower than in a 
selection of European countries (10-32%). We are especially interested in the tendencies of doctors 
to discuss LARC methods in order to determine whether part of the explanation for the relatively low 
uptake of LARC is reluctance on the part of some doctors to even discuss these products. Such an 
investigation has the potential to provide new evidence to inform policy discussions where, for 
example, calls to incentivize general practitioners (GPs) to provide LARC information (Black et al. 
2013) are predicated on GPs not currently providing such information.  
A stated preference (SP) choice task is developed and implemented using a sample of Australian 
GPs. For a sequence of hypothetical women, each defined by a set of personal characteristics, GPs 
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were asked to indicate which specific contraceptive products would form the consideration set to be 
discussed with the patient. Research designs where real doctors evaluate hypothetical patients have 
been implemented in a number of different contexts and with a range of methods. What we are 
doing is often called a clinical vignette; see Peabody et al. (2004). Sometimes the vignette is 
presented in the form of a videotaped patient portrayed by an actor; see Lutfey et al. (2009). 
Validation of such approaches has been undertaken by Peabody et al. (2004) where the gold 
standard method was taken to be standardized patients where again trained actors simulate a 
patient but where the encounter involves face-to-face interaction with the doctor. A variant of this 
approach has been used by Currie et al. (2011) and Lu (2014) in field experiments where the actor 
portrays a family member who is consulting the doctor on behalf of a distant relative; this type of 
interaction is not uncommon in China where these studies were conducted. Our point of difference 
is to use SP methods common in discrete choice experiments (DCE); see Louviere et al. (2000) and 
Street and Burgess (2007). This approach delivers advantages in terms of a wider coverage of the 
type of patients considered and cost effective collection of data by requiring doctors to evaluate 
multiple patients.  
This is not a standard DCE of the type common in health economics where a fixed context is 
provided and the attributes of the products in the choice set are varied. For example, Hole et al. 
(2013) describe a particular patient and then ask doctors to choose between two hypothetical drugs 
where it is the attributes of the drugs that vary over choice occasions. Instead, we experimentally 
manipulate the patient characteristics and keep the alternatives fixed. In each scenario the GPs 
encounter a different hypothetical woman and are asked to match them to a fixed but 
comprehensive range of contraceptive products identified by generic labels. This leads to another 
feature that distinguishes our work from standard DCEs and other applications involving 
hypothetical patients. By focussing on the discussion stage of the clinical encounter rather than the 
ultimate recommendation that is made, the econometric analysis must accommodate outcomes 
that involve choices of multiple products rather than the typical situation where a single choice is 
the outcome of interest. 
 
Analysis of these data confirms that in many situations only a subset of products is in fact discussed. 
We are also able to identify clinical, life-cycle and socio-demographic characteristics of women that 
are important in shaping the form of the consultation, as defined by the products discussed, to 
identify variations associated with GP characteristics and to quantify the impact of the specified 
sources of complexity. Using our econometric results we simulate predictions of the probability that 
particular products are discussed to highlight that GPs (of all persuasions) are almost certain to 
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include the Combined Pill in their consideration sets for a wide class of women where there is no 
clinical reason to restrict the products to be discussed. While there is consensus amongst GPs about 
discussing the Combined Pill, no such clear agreement emerges for any of the individual LARC 
methods. Movement away from the Combined Pill towards LARC products is in part associated with 
patient complexity. But these tendencies interact with substantial doctor specific heterogeneity 
associated with all contraceptive products other than the Combined Pill.  These estimated effects 
are consistent with many of our doctors reverting to “ready-to-wear” or norm-based choices.   
 
 
2. The expert’s choice problem and econometric framework  
The stylized version of the interaction that underpins our analysis, involves an expert, who can be 
characterized as being more informed about the alternatives available than the decision-maker who 
ultimately needs to make the choice. The expert needs to convey information to the decision-maker 
and does so by choosing to discuss a subset of alternatives, the consideration set, before making a 
recommendation. The individual subsequently makes a decision on the basis of all the information 
she has acquired, including that conveyed by the expert. While what follows is relatively general it 
will be convenient to focus on our application and hence refer to the expert as a doctor, the 
decision-maker as a patient and the choice set as a range of alternative prescribed products. 
 
Doctors need to evaluate alternative prescribed contraceptive products and determine how they 
match their patient described by her particular preferences, clinical indicators and personal 
characteristics. The choice being made by the doctor is whether or not to discuss each of the 
products in the universe of possible products with a particular woman. Within a random utility 
framework the benefit of discussing the jth product is represented by:  
 (1)  𝑈𝑗 = 𝑉𝑗 + 𝑢𝑗; 𝑗 = 1,⋯ , 𝐽. 
 
𝑉𝑗 represents the predictable component of the overall utility of discussing product j. We refer to 
𝑉𝑗 as the “index” which will be specified as a function of observable characteristics of the patient, the 
product and the doctor. Choosing to discuss product j requires a comparison with the benefit of not 
discussing denoted by 𝑈0 where for identification purposes the predictable component is 
normalized to zero. Under the assumption of independently distributed Type-I extreme value 
stochastic error terms the probability of discussing the product takes the form: 
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(2)  𝑃𝑃𝑃𝑃(𝑦𝑗 = 1) = 𝑃𝑃𝑃𝑃(𝑈𝑗 − 𝑈0 > 0) = exp (𝜎𝑉𝑗)1 + exp (𝜎𝑉𝑗) 
 
where 𝜎 is the scale parameter which would be set to unity in the case of a standard binary logit 
model.  For our modelling this scale parameter plays a critical role. Heiner (1983) and de Palma et al. 
(1994) emphasize the likely variation in the ability or willingness of decision-makers to accurately 
evaluate alternatives and translate this into variance or scale heterogeneity. Complexity adds extra 
noise to the error term in this random utility framework. If there is variation in scale across the 
population of doctors then a small scale (large variability) is associated with more random behavior:   
 (3)  lim
𝜎→0
𝑃𝑃𝑃𝑃(𝑦𝑗 = 1) = 0.5. 
 
As choice behavior becomes more random the probability of the product being discussed is as likely 
as not being discussed irrespective of the product specific net benefits identified in 𝑉𝑗. This captures 
the tension in the choice problem discussed by Frank and Zeckhauser (2007) who distinguish 
between “custom made” and “ready-to-wear” or norm-based choices. A custom made choice 
involves the doctor undertaking a careful evaluation of the patient and then matching them to an 
appropriate product. In terms of the model, the index is accurately assessed and this drives the 
choice with little role for uncertainty on the part of the decision-maker. Alternatively, as new 
products are introduced, doctors face considerable costs in the process of gaining the knowledge 
and expertise required to discuss and prescribe these products. This is particularly the case when 
more familiar and acceptable products are available even though they may be somewhat inferior to 
the new products. This is an especially salient cost in our situation.  Allowing for scale heterogeneity 
captures the tendencies of some doctors to adopt norms (here particular products) that work well 
for a broad class of women and to place less weight on certain patient attributes that would indicate 
a different product that is potentially a better match. Observing doctor choices across multiple 
products for different women provides some evidence on the source of doctor heterogeneity.  
 
In order to generate a measure of patient complexity, we follow Swait and Adamowicz (2001) and 
equate patient complexity with uncertainty about the ultimate recommendation. In cases where the 
recommendation is clear one alternative will have a probability of being recommended that 
approaches unity. At the other extreme a complex patient will be one where opinion is divided 
amongst products and the distribution of probabilities across products is uniform.  Entropy captures 
such uncertainty and is defined as: 
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 (4)  𝑒𝑡 = −� 𝑝(𝑗, 𝑡)𝑙𝑃𝑙�𝑝(𝑗, 𝑡)�𝐽
𝑗=1
, 
 
where 𝑝(𝑗, 𝑡) is the probability that product j is recommended by the doctor for woman t. This 
measure achieves a minimum of zero when one product is certainly chosen and a maximum of log J 
when all products are equally likely.  
 
It could be the case that norms are used in response to more complex patients where there are high 
cognitive costs associated with matching them to appropriate products. Thus patient complexity can 
have an effect on the evaluation of the woman that is captured in 𝑉𝑗 and it is possible for this to 
interact with doctor heterogeneity.    
 
These considerations lead to our general model specification that is a form of GMNL, Fiebig et al. 
(2010), where we allow for patient complexity, scale heterogeneity and their interaction. For a 
representative product this is given by:  
 (5)  𝑦𝑖𝑖∗ = (𝛾0𝑖 + 𝛾1𝑖𝑒1𝑖𝑖 + 𝛾2𝑖𝑒2𝑖𝑖)𝜎𝑖 + a𝑖𝑖′ (𝛿𝜎𝑖) + z𝑖′(𝜋𝜎𝑖) + 𝜀𝑖𝑖; 𝑖 = 1,⋯ ,𝑁; 𝑠 = 1,⋯ , 𝑆; (6)  𝛾𝑘𝑖 = 𝛾𝑘 + 𝜂𝑘𝑖; 𝜂𝑘𝑖~𝑁(0,𝜔𝑘2) (7)  𝜎𝑖 = exp(𝜎� + 𝜏𝜈𝑖);  𝜈𝑖~𝑁(0,1) (8)  𝑦𝑖𝑖 = 1[𝑦𝑖𝑖∗ > 0] 
where 𝑦𝑖𝑖
∗  represents the latent net evaluation that doctor i assigns to discussing this contraceptive 
product when faced with choice scenario s representing a particular woman and this is related to the 
observed binary outcomes, 𝑦𝑖𝑖, according to equation (8). Note that 1[.] is the indicator function.  
 
The vector of explanatory variables 𝑎𝑖𝑖  contains attributes of the hypothetical women while 𝑧𝑖  
represents the vector of observed characteristics of our sample of GPs. The associated vectors of 
coefficients denoted by 𝛿 and 𝜋 represent how the attributes of women and characteristics of GPs 
impact the probability of discussing this contraceptive product.   
 
Recall that product attributes are not included and therefore the constant (𝛾0𝑖) in (5) captures the 
evaluation of this product conditional on patient attributes. This is likely to be GP specific and even 
though we control for observable GP characteristics we specify it as a random parameter in order to 
capture unobservable GP effects and to control for the likely correlation across the multiple choices 
being made by each GP. Patient complexity is captured by allowing the constant to also vary across 
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the three levels of entropy where 𝑒1𝑖𝑖and 𝑒2𝑖𝑖 represent medium and high entropy so that low 
entropy is the base case. These entropy effects are also allowed to vary across doctors and this 
specification is equivalent to assuming error components that induce heteroskedasticity associated 
with higher levels of patient complexity. While this particular specification is a priori sensible, 
sensitivity checks were performed to confirm this specification decision.  These random coefficients 
are all assumed to be normally distributed.  
 
Note that we are not necessarily assuming that GPs are making these decisions to maximize the 
utility of their patients. Specifically, the presence of GP effects, conditional on patient 
characteristics, allows the possibility that GPs shade their choices to, in part, reflect their own 
preferences or expertise. GP-specific affects are also assumed for scale. In specifying the distribution 
of scale heterogeneity, 𝜎�  is a normalizing constant required to ensure identification. This is achieved 
by setting: 
 (9)  𝜎� = 𝜏22 ⇒ 𝐸(σi) = 1. 
 
One attraction of the specification of scale heterogeneity given in (7) is a considerable amount of 
flexibility with the addition of only one parameter, 𝜏. This parameter provides a measure of scale 
heterogeneity and if 𝜏=0, the GMNL model reduces to a mixed logit specification with random 
parameters for the patient complexity effects.  
 
 
3. Choice task  
While market or revealed preference data are available that characterize the contraceptive choices 
different types of women are currently making (Yusuf and Siedlecky (2007) and Gray and McDonald 
(2010)) and the products GPs are prescribing (Mazza et al. 2012), these data provide little or no 
detailed information about the interaction between the patient and the doctor. SP methods provide 
a natural methodology to learn more about this particular choice process.  
 
The choice task was developed to reflect a typical consultation between a woman and her GP in 
relation to contraception but with a focus on the GP’s decision about which products they would 
discuss and ultimately recommend. In doing so we abstract from the product attributes and instead 
focus on how the patient characteristics impact on the choices of the GP.  
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The actual choice task reflected findings from a literature review and was strongly guided by focus 
groups conducted with GPs in Australia.  The focus groups were conducted by one of the clinical 
authors, an expert in reproductive health. Specifically, the participants were asked to consider the 
issues and options they would discuss with three hypothetical women, who were chosen to cover a 
range of different life cycle and fertility stages. GPs identified what options they would discuss with 
the women, the extent to which they would take their previous contraceptive history, likes and 
dislikes into account, the reasons they would counsel against specific types of contraceptives and 
what personal characteristics and contraceptive attributes they believed were of most relevance and 
importance in each specific situation. Focus group discussions were recorded and transcribed, and a 
thematic analysis was undertaken by two of the authors.   
 
In the choice task, doctors were asked to consider a context where a patient is seeking information, 
advice and possibly a prescription for contraception.  As GPs were considered to be knowledgeable 
about the attributes of contraceptive products in the Australian market, and this was supported by 
the findings from the focus group discussions, the choice task did not specify the product attributes 
apart from a label.  GPs were asked to consider a series of hypothetical patient encounters described 
in terms of the characteristics of the woman (her health, her life stage and contraceptive experience 
and her smoking and socioeconomic status), and then to consider which products they would discuss 
with the woman, and which specific product they would recommend. Each woman patient is 
described by a set of attributes that form the experimental design. The final set of attributes and 
levels are provided in Table 1. A benefit of this approach is that, compared with clinical vignettes 
(Peabody et al., 2004), it allows us to include a broader range of attributes, and facilitates the 
doctors being presented with a larger number of scenarios than would otherwise be possible.  
 
==Table 1 about here== 
 
Nonetheless, it is only feasible to show a subset of the (44x36x22) =746,496 possible “women” to the 
GPs. As we wanted to allow for potential interactions between age and fertility plans (each with 4 
levels) we needed to construct an attribute with 4x4=16 levels. Then the 15 degrees of freedom 
associated with this attribute would correspond to 3 degrees of freedom for the main effects of each 
of the attributes “age” and “fertility plans” and 9 degrees of freedom corresponding to the 
interaction between these two factors. We needed to construct an attribute with 12 levels to 
estimate the interaction between “periods” and “reason for encounter”. Kuhfeld (2006) contains no 
design with two factors, one with 16 levels and one with 12 levels. A standard construction method 
in this case (see for example, Construction 2.3.8 in Street and Burgess, 2007) is to choose one of the 
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factors with 4 levels in the design with 64 runs. The whole design is repeated three times but with 
different names for the levels of that one factor in each of the repetitions of the design. So there are 
4 levels in each of 3 designs giving a factor with 3x4=12 levels in total. Thus, 192 “women” in total 
are divided randomly into 12 versions of 16 women each. The attribute descriptions were worded 
such that implausible combinations were rare and unlikely to be included in the design. That is, there 
were very few combinations of attributes defining a particular woman that were not at least 
feasible.  
 
Doctors were asked to answer a sequence of three questions pertaining to each particular patient. A 
stylized version of the entire choice task for one woman is provided in Figure 1. The predominant 
method of contraception amongst Australian women is a form of the contraceptive pill (Gray and 
McDonald, 2010). Thus, for the first question doctors were asked to decide whether they would 
confine their discussions of contraceptive options according to three pre-specified and broadly 
defined sets of products: (i) contraceptive pills only; (ii) methods other than contraceptive pills; or 
(iii) contraceptive pills and other methods. Then, the second question required the GP to indicate 
which specific contraceptive products, constrained by the broad category they chose in the first 
question, would form the consideration set to be discussed with the patient. The third and final 
question required the GP to choose one product that they would recommend as best suited to the 
patient. Again this third choice was restricted to the products specified in the previous question. 
Thus at no stage in the sequence of questions were respondents permitted to make inconsistent 
choices. The focus here is on the outcomes from the second question where the consideration sets 
are defined. Because of the structure of our choice task some of these decisions about whether to 
consider a product or not was effectively made in answering the first question about broad product 
types. The recommendation data are not explicitly modelled here but are pursued in Fiebig et al. 
(2015).  
 
==Figure 1 about here== 
 
The products are identified by labels and, as mentioned above, attributes of products are not 
specified as part of the experiment.  The nine products that were considered are the Combined Pill, 
the Mini-pill (progestogen-only pill), Hormonal Injection, Hormonal Implant, Hormonal Intra-uterine 
Device (Hormonal IUD), Hormonal Patch, vaginal Ring, copper IUD and Condoms. Our emphasis was 
on prescribed products but expert advice from our clinical authors was that it would be more 
realistic to include Condoms as part of the list of products that would likely be discussed, particularly 
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given that doctors may discuss these in addition to a prescribed product for dual protection against 
Sexually Transmitted Infections (STIs). The vaginal Ring was relatively new to the Australian market 
and the Patch was not available at all. Doctors were expected to have some knowledge of the 
attributes of the Ring and Patch because of their existence in other countries. 
 
The choice task was completed on-line. The sample frame for the GPs was a list of 14,816 GPs from 
all states and territories of Australia estimated to be approximately 81% of all recognised GPs 
currently practicing in Australia. The list was randomised and 1,834 GPs were approached by a 
phone call and follow-up fax inviting them to participate in the study. 1,512 responded and 177 
agreed to participate. As has been found in other studies, the response rate for GPs was low (Britt et 
al., 2008). Because of this, the sample was augmented through advertising in GP newsletters and 
forums and a further 44 GPs volunteered to participate. 162 GPs completed the study between 
December 2008 and June 2009, 22 of whom were volunteers. GP participants were offered $A100 
remuneration for their time, paid on completion of the choice tasks. 
 
 
4. Data and summary statistics 
In the first question GPs indicate which of three broad product categories they would discuss with a 
specific patient. The raw frequencies across all 2592 choice occasions indicate that GPs will 
sometimes confine their discussions to “pills only” (3%) or “methods other than pills” (22%) but in 
the vast majority of cases (75%) they consider a mix of “pills and other methods”.  
 
In the second question GPs chose what we are calling a consideration set comprising a subset of 
particular products. It is these outcomes that are our primary data for analysis. Over all choice 
occasions by all GPs, the median and modal number of products discussed is 4 and in less than 1% of 
choice occasions did GPs indicate they would discuss all products. These basic results indicate the 
existence of consideration sets whereby GPs almost always discuss a subset of available 
contraceptive products with patients. At the other extreme, on 4.3% of choice occasions the 
consideration set was a solitary product and a majority of these (52%) were when the GP said they 
would only discuss the Combined Pill. 
 
The first column of Table 2 provides the relative frequencies with which each of the products 
appeared in a consideration set. For comparison, this table also provides the relative frequencies of 
the choices made in the third choice task, i.e. those products that were ultimately recommended by 
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the GPs. The final column labelled “conversion” gives the recommendations expressed as a 
percentage of the times the product was considered.  
 
The conversion percentages highlight two key features. The Combined Pill, Implant and Hormonal 
IUD are distinctive because they are very likely to be discussed and conditional on being discussed 
are quite likely to be recommended. In contrast Condoms, Ring and Injection are quite likely to be 
discussed but their very low conversion rates indicate they are relatively less likely to be 
recommended. For Condoms this is not unexpected given that doctors are likely to discuss these in 
conjunction with prescribed products in the context of STI protection and hence not subsequently 
recommend them for contraception. 
 
Across all 2592 observations the Hormonal Patch was rarely considered and was only recommended 
on 0.5% or 13 occasions. This is possibly not surprising given its unavailability in Australia which may 
have led to unwillingness on the part of GPs to choose this alternative even in a hypothetical setting 
where the product is assumed to be available. Nonetheless the Ring, which is only very recently 
available in Australia, was much more likely to be considered and even recommended.  
 
In order to derive our measure of patient complexity a multinomial logit model is estimated using 
the recommendations data. The predicted probabilities for each of the products, except the Patch, 
were used to predict entropy for each of the 192 distinct women in the design. These are then 
categorized into low (11%), medium (40%) and high entropy (49%) cases. The high entropy women 
are more likely to be older, have irregular periods, elevated blood pressure and plans to have 
children in next 2 years. Low entropy women are almost certainly younger (<29) and have children 
but are not breastfeeding and are very likely to have normal blood pressure. 
 
A number of GP characteristics were included in the subsequent analyses. They are the GP’s age, 
gender, whether they were a Fellow of the Royal Australian College of GPs (RACGP), whether they 
have a Family Planning Certificate, whether they bulk billed (implying patients face no out-of-pocket 
expenses) whether they graduated from an Australian medical program and whether their practice is 
located in an urban area. Table 3 provides some summary statistics on these key characteristics of 
the doctors in the sample. Comparing characteristics of our GP sample to the Australian population 
of GPs and other national samples of GPs, (Britt el al., 2008), we find our sample to be 
representative in terms of age, location, practice characteristics and bulk-billing rates. The 
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proportions of female GPs and those who were Fellows of the RACGP however were higher, 
reflecting the likelihood that this sample was more engaged in reproductive health than other GPs.  
 
==Tables 2 & 3 about here== 
 
5. Estimation results  
The outcomes of interest are a set of nine binary indicators corresponding to each of the 
contraceptive products and which denote whether or not the GP said they would discuss that 
particular product given the hypothetical patient. While this effectively represents a system of 
binary choice equations where there is likely to be cross-equation correlations, the advantages of 
joint estimation of such a complete specification are confined to increased efficiency of estimates. 
Because each of the equations contain the same set of regressors, efficiency gains are likely to be 
minimal. In the classical seemingly unrelated regression case there are no gains from joint 
estimation; see Fiebig (2001). Thus models described by (5) – (8) were estimated separately for each 
product by maximum simulated likelihood; see Gu et al. (2013) for more detail.  
 
5.1 Comparison of model fit  
In order to provide some indication of the relative contribution of the two sources of complexity a 
sequence of alternative specifications are estimated and their relative fit compared. As a baseline 
model consider a random effects logit specification (M1) where 𝛾1𝑖 = 𝛾2𝑖 = 0 and 𝜏=0 implying both 
sources of complexity are ignored.  Then patient complexity (M2) and GP scale heterogeneity (M3) 
can be added separately. Finally our general GMNL model (M4) is estimated where both features are 
included. In order to compare the improvement in fit McFadden’s R-squareds are reported with the 
simulated log-likelihood of the random effects logit (M1) specification as the base.  
 
==Figure 2 about here== 
 
The improvement in the M4 fit is marked. M4 nests the other models and LR tests comparing M4 to 
M1 confirms significant improvement in fit for all products. But a comparison across products 
indicates considerable variation in the relative impact of sources of complexity on fit. Introducing 
patient complexity in M2 typically yields modest improvements compared to accounting for scale 
heterogeneity in M3 despite M3 being the more parsimonious model. Moving from M1 to M2 
involves 4 additional parameters while M1 to M3 requires only a single additional parameter.  
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The Combined Pill is a notable exception to this superiority of M3. Here patient complexity has a 
relatively large impact on fit and GP scale effects are relatively small. The Condom is the only other 
product where M2 fits better than M3 although for the Mini-pill both forms of complexity have 
comparable impacts on fit. For the other products, M3 typically fits dramatically better than M2; see 
especially the IUD and Ring. For the Ring it is clear that the M4 improvement is almost all due to GP 
scale effects. In several cases there seems to be an interaction effect between the two sources of 
complexity, this is especially evident for the Implant.   
 
The fit statistics for the Patch have been included but here M3 and M4 are somewhat different 
variants of the model estimated for the other products. Because of the rarity of this product being 
considered (more than 80% of GPs never chose this product in any of their 16 scenarios) there were 
convergence problems with the GMNL specification in (5) associated with 𝜏 becoming excessively 
large to accommodate the choice patterns. Fiebig et al. (2010) made note of this extreme form of 
variability and suggested not scaling the alternative specific constant as a solution. This is the variant 
of the M3/M4 models reported here for the Patch. Because this represents a special case making 
comparison with other products difficult and because of the rarity of it being considered, we will not 
pursue further discussion of this product.    
 
While these comparisons confirm improvements in fit, it is important to check how improved fit 
impacts substantive findings. Presenting these estimation results efficiently and informatively poses 
a major challenge.  Thus a full set of estimation results for each of the contraceptive products is not 
presented but is available on request. Instead, selected results are provided relying heavily on a 
range of graphical summaries. The selection of results is driven by our focus on the impact of 
complexity and in particular on LARC methods and the main aim of obtaining a better understanding 
of their role in the discussion of contraceptive options between GPs and patients. 
 
5.2 Estimated impact of complexity on the probability of being discussed  
First consider scale heterogeneity and recall that τ =0 would imply no scale effects and when there is 
a non-zero τ, scale is normalized to have a mean of unity. The τ estimates together with their 95% 
confidence intervals are provided in the left hand panel of Figure 3. The uniformly significant τ 
estimates were anticipated from the considerable improvement in fit provided by M3. There is also 
considerable logic to the relative magnitudes across products. The most common and best known 
contraceptive is the Combined Pill and it is associated with the least amount of GP variability.  
Conversely the products with the 3 largest amounts of GP variability are the IUD which is being 
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superseded by the Hormonal IUD; the Ring which is the newest and least known product; and the 
Implant where there seems to be extremely divergent views across GPs.  
 
Significant GP effects, which are present here for all products, manifest themselves in a range of 
scale values across GPs that imply the estimated index parameters get scaled up or down depending 
and whether the scale is greater or less than unity. Moreover, as τ increases the scale distribution 
becomes more heavily skewed to the right while keeping the mean equal to 1. To assist in 
interpretation and to better understand the implications of alternative τ values consider the 
estimated median of the scale distribution together with their 95% confidence intervals that are 
presented in the right hand panel of Figure 3. The relatively low estimated τ for the Combined Pill 
implies a modest amount of scale heterogeneity and a median scale effect that is not significantly 
different from unity.  
 
==Figure 3 about here== 
 
At the other extreme the large τ estimate for the Implant implies considerable GP scale 
heterogeneity and the estimated median is now only 0.13. Even though the distribution has a mean 
of unity, with large amounts of heterogeneity the distribution of scale is highly skewed. For the 
Implant the choices being made by the GPs are subject to huge scale effects and thus for a given 
index comprising particular GP/woman combinations the probabilities can be very different 
depending where we are in the scale distribution. The same is true to a somewhat lesser extent for 
the ring and IUD. The HIUD, Condom, Injection and Mini-pill are an intermediate cluster. 
 
The results for patient complexity are presented separately for the mean (Figure 4) and variance 
(Figure 5) effects. Our specification has low entropy as the base and the estimated effects of 
medium and high entropy patients are relative to this base. Choice of the base when dummy coding 
in random coefficient models imposes constraints of the implied form of heteroskedasticity but we 
checked for such coding sensitivity and this specification proved appropriate. This is in part due to 
patient variance effects not being overly significant and hence not important in terms of improved 
fit.  
 
==Figures 4 & 5 about here== 
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Amongst the LARC all except the IUD exhibit significant patient complexity mean effects.  The 
Implant, HIUD and Injection are all more likely to be discussed in higher entropy patients. Because of 
the differential scaling effects we need to be careful in comparing magnitudes of effects across 
products. For example, the large Implant effects will tend to be scaled down. Amongst the non-LARC 
products there are significant shifts in the mean associated with both pills. For the Mini-pill again 
there is a tendency for higher complexity to have a positive impact but the reverse is true for the 
Combined Pill. The variance effects are modest. Only for the Implant are there significant variance 
effects at both levels. 
 
5.3 Comparison of predicted probabilities across models  
The estimated models can be used to generate predictions of whether a product is discussed and 
these can be informative about the impact of accounting for complexity. Figure 6 displays a 
comparison of density plots of the predicted probabilities of discussing the Combined Pill generated 
by the baseline M1 model and the full M4 model. These are provided for all within sample GP-
women combinations and then separately for the women characterized by the three levels of 
entropy.  
 
For the Combined Pill, the impact of accounting for complexity is most pronounced in the low 
entropy regime. Even without modelling complexity, it is clear that predicted M1 probabilities are 
large with little variation. These two key features are reinforced after including complexity in M4.  In 
the high entropy regime there is a noticeable shift to the left in the density. 
 
Figure 7 provides a comparable set of plots for the Implant. Again explicitly modelling complexity 
matters for predictions although here there are similar effects over entropy regimes. Recall that this 
was a product where interaction between the sources of complexity mattered. On one hand this is 
the product chosen most often to be discussed and was a product where patient complexity was 
significant. But despite many GPs indicating they would discuss the Implant, there are some GPs who 
never discuss it. In order to capture this considerable GP diversity the variability in scale is large. The 
appearance of a tendency to “Bimodality” in part reflects tension between willingness to discuss 
that suggests high predicted probabilities and large scale effects which imply some of these large 
probabilities get muted.  
 
==Figures 6 & 7 about here== 
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Similar graphs for each of the products have not been presented but they do indicate an impact 
albeit not as stark as the two extreme cases that have been provided. 
 
5.4 Comparison of predicted probabilities across women  
Table 4 provides the mean and the range of predicted probabilities for all within sample GP-women 
combinations for all products. These are the same predictions used to generate Figures 6 and 7.  It is 
important to note that these results are not expected to reflect market shares for actual product use 
because: (i) they are not choices made by women (or even recommendations made by GPs); (ii) the 
design is chosen to induce trading and not to reflect actual behaviour; and (iii) we included a product 
(Patch) that is not available on the Australian market. 
 
The means of the predictions essentially mimics the summary statistics presented in Table 3. What is 
new relative to the summary statistics is the extent of variability in the predictions. Across the board 
there is considerable variability reflecting both the range of women presented for evaluation and GP 
effects. In part, this is to be expected. Within the controlled environment of the SP choice task, a 
primary aim is to choose attribute levels in order to encourage trading which, in turn, will lead to 
variability in outcomes. So in some sense the choice task would be considered a failure if we did not 
observe such variability. 
 
==Table 4 about here== 
 
Because the focus is on LARC and the fact that clinical guidelines supports their use as first line 
contraceptives for women of all reproductive ages, we are interested in what GPs say they would 
discuss with “low risk” women. Such a woman would have no clinical, life cycle or preference related 
attribute that should a priori deter GPs from discussing LARC. Our “Baseline” woman defined in 
Table 1 by the set of omitted categories in our dummy coded model specification is such a case. She 
is 20-29, starting prescribed contraception for the first time, has no problems with periods, has 
normal blood pressure, is in a new relationship, has no children but plans to have children but not in 
the next 2 years, has no strong opinion about the pill, is not concerned about gaining weight, has no 
difficulty with compliance, has low to middle household income and is a non-smoker. There is 
nothing here that should deter GPs from saying they would discuss LARC. The middle section of 
Table 4 provides predictions for our low risk woman. The overall compression of the range of 
predictions is to be expected as one of the possible distinct women in our design has been isolated. 
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Any remaining variation in predictions is attributable to the combined impact of GP effects and the 
mix of associated GP characteristics in our sample.  
 
Possibly the most dramatic feature of these results is the change in the Combined Pill. Our model 
predicts that GPs (of all persuasions) are almost certain to include the Combined Pill in their 
consideration sets. Amongst the LARC products, the Implant and Injection have small increases in 
popularity and exhibit somewhat less variability but neither effect is as dramatic as that observed for 
the Combined Pill. The other two LARC products move in the opposite direction with the mean 
predictions for the Hormonal IUD and IUD both decreasing. The results indicate that these two 
products together with the Mini-pill are unlikely to feature in the consideration set for the low risk 
woman.   
 
There are a number of dimensions in which we could change the baseline characteristics to define 
alternative “low-risk” women without seriously disrupting the overall pattern. For example, ageing 
our Baseline woman (holding all else constant) would lead to large increases in the predicted 
probabilities of the Hormonal IUD being discussed but other changes would be relatively minor. This 
indicates that the key features of the results are representative for a relatively broad class of woman 
and are not confined to the baseline characteristics.   
 
The variation in the LARC predictions is associated with both GP scale effects and observable GP 
characteristics. For the Implant, being trained in Australia and having a Family Planning Certificate 
were both positive and significant effects in explaining the consideration choices. If we simulate a 
situation where all of our GPs have these two characteristics then the mean prediction of 
considering the Implant increases from 0.727 to 0.796 and so even here the Implant does not reach 
the levels of the Combined Pill. What’s more, considerable variation still remains with the 
predictions ranging from 0.683 to 0.898.  
 
From the range of predictions across the entire sample, we know that there are situations where the 
probability of discussing the Combined Pill can be relatively low. An interesting scenario to 
investigate is what happens when GPs are faced with a woman with risk factors that deter discussing 
the Combined Pill. An example of such a “some risk” woman would be one who is breastfeeding and 
has high blood pressure but has the baseline level for all other attributes. The predictions for this 
woman are presented in the right hand section of Table 4. Essentially there seems to be a 
substitution to the Mini-pill. For this woman the mean predicted probability for the Combined Pill 
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declines from 0.979 to 0.454 while the Mini-pill increases from 0.168 to 0.567. Amongst the LARC 
products there is no comparable change although the Hormonal IUD mean prediction increases from 
0.092 to 0.285 and the IUD from 0.166 to 0.288.  
 
 
6. Discussion of results  
Our analysis predicts that GPs (of all persuasions) are almost certain to include the Combined Pill in 
their consideration sets for a wide class of woman not too different from our low-risk (Baseline) 
woman. While there seems to be considerable consensus amongst GPs about discussing the 
Combined Pill, no such clear agreement emerges for any of the individual LARC methods. In part, the 
Combined Pill result reflects the actual, current choices of Australian women and hence represents 
an entirely rational decision on the part of GPs. Given the current evidence supporting the use of 
LARC for these women, the question is why there isn’t a similar result for a LARC option. The Implant 
comes close. While it is included in the consideration sets of GPs on more choice occasions than any 
other product, for the low risk woman it does not reach the levels of certainty of being discussed 
displayed by the Combined Pill. In particular, this product exhibits the highest levels of GP 
heterogeneity reflecting divided reactions amongst GPs.  
 
This comparison needs some qualification because we are taking a snapshot at one point in time and 
comparing the Combined Pill with LARC products, where the former has been available and popular 
for an extended period while awareness and product knowledge is still developing for the latter. It 
could be that LARC acceptance amongst doctors is increasing. Some support for this scenario is 
provided when we model more highly qualified GPs who were trained in Australia. This increases the 
rate at which the Implant was considered for low risk women, even though the Combined Pill 
remains the dominant single product.  
 
It is highly likely that the unwillingness of GPs to discuss LARC relative to the Combined Pill is 
associated with their experience with the effectiveness of the Combined Pill that has grown over the 
past 50 years. Both GPs and women are so comfortable with the idea of the Combined Pill as a 
relatively cheap, safe and effective form of contraception that everything else is considered in 
relation to it. Conversely, GPs were willing to customize their discussions of the Combined Pill with 
particular women. For this product, more than any other, the decision whether to discuss or not was 
associated more with the characteristics of the women than heterogeneity of the GPs. It is true 
though that our comparison of the women with no risk factors versus those with some risk factors 
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suggests that when GPs more away from the Combined Pill, the Mini-pill is a likely replacement in 
the discussion rather than a LARC.  
 
There are a number of costs that form impediments to LARC products reaching the level of 
consensus associated with the Combined Pill. As new products are introduced, doctors face 
considerable costs to gain the knowledge to be able to discuss and prescribe some of these 
products. This is particularly the case when the more familiar pills are available even though they 
may be somewhat less effective than the newer LARC products.  
 
Even if a GP has acquired knowledge about the efficacy of LARC and which LARC products are 
suitable for a particular type of woman, it is unlikely that s/he will discuss a product with a woman 
unless s/he can also be confident about prescribing and providing it. This is more difficult in relation 
to LARC products than for the Combined Pill as the GP has to either acquire the knowledge and 
expertise to insert the Implant or IUC methods or be willing to refer their patients elsewhere.  
 
There is also the issue of the economic incentives facing the woman; while  LARC products except for 
the copper IUD are subsidised by the Pharmaceutical Benefits Scheme (PBS), so are many brands of 
the Combined Pill and the upfront cost of the latter is lower than for an implant or IUD methods 
which generally requires an additional insertion cost. It is also the case that prescription of a LARC 
often necessitates a second consultation (either with a GP, specialist or Family Planning Clinic), more 
inconvenient than filling a script for the Combined Pill and likely to be associated with an out-of-
pocket cost to the woman. The Medicare rebate system in Australia may also discourage GPs from 
inserting LARC, particularly the Hormonal or copper IUD, as the rebate is low relative to the time, 
equipment and skills involved.  
 
Our results pose something of a challenge for enhancing LARC uptake in Australia, given increasing 
evidence of their greater effectiveness in preventing unwanted pregnancy.  They suggest the need 
for greater education of GPs of their benefits and suitability. Even for the Implant, which was a 
popular choice for discussion, there was considerable variation across GPs possibly reflecting the 
impact of some of the costs mentioned above on some doctors. A possibly more worrying result is 
evident in the simulation for the low risk woman where there was little support for discussing the 
Hormonal IUD.  This suggests that the suitability of intrauterine methods for younger women as well 
as those in new relationships has not yet become widely accepted. Instead they seem to be viewed 
as one of the products that get considered when the Combined Pill becomes problematic. 
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Our results indicate support for LARC amongst GPs but this support is not uniform nor is it at the 
level enjoyed by the Combined Pill. It should be acknowledged that the analysis is based on a 
potentially biased sample in terms of the GP participants being more interested and informed about 
contraception.  The context of our choice task also encourages the idea of discussion of different 
products as it involves a woman explicitly consulting the GP for “information, advice and potentially 
a prescription”. If these two aspects have introduced any biases it is likely to manifest itself in a 
greater propensity to discuss LARC which would only reinforce the tendencies we have documented.   
 
 
7. Conclusions  
Maintaining good reproductive health requires women to have access to information about safe, 
effective and affordable methods of contraception. By exploiting SP methods we have been able to 
provide new insights into medical decision-making in the particular case of GPs providing such 
information in a discussion of potential contraceptives with women. Our analysis for Australia points 
to less than universal support for discussing LARC in cases where best practice guidelines suggest 
this is appropriate. This provides evidence that part of the explanation for relatively low uptake of 
LARC methods is a reluctance on the part of GPs to recommend or even discuss them. Evidence of 
significant GP specific effects reflecting norm-based practices associated with whether LARC 
methods are discussed suggests greater investment in the education and training of GPs may be 
warranted and particularly for those GPs who were not educated in Australia. Australia currently has 
no national policy promoting LARC awareness and provision at either the health care professional or 
community level unlike in the UK and US.  
 
Our primary focus has been on the GP providing information to women. It could be true that low 
LARC uptake partly reflects a general lack of community awareness so that women simply aren’t 
asking for fuller discussions of contraceptive options and GPs are not being proactive in initiating 
such discussions. Importantly, our results condition on the interaction between the GP and the 
woman. While such an interaction is required for prescribed contraceptives, other popular 
contraceptive products (especially Condoms) do not require a prescription. For both these reasons, 
policies that incentivize GPs to provide LARC information (Black et al. 2013) can only be part of the 
response. It is necessary to ensure such information flows to women, especially young women, from 
additional sources other than GPs and so that ultimately women are making a fully informed 
contraceptive choice.    
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Table 1: Attributes and their levels 
Age  
dagegp 1 Aged 16-19 years 
dagegp2 Aged 20-29 years 
dagegp3 Aged 30-39 years 
dagegp4 Aged 40 years or more 
Current status  
drfe1 Starting prescribed contraception for first time 
drfe2 Recommencing prescribed contraception 
drfe3 On  pill but dissatisfied  
drfe4 Using non-pill method but dissatisfied  
Periods  
dbleed1 Heavy and/or painful periods 
dbleed 2 Irregular periods 
dbleed 3 No problems with periods 
Blood pressure  
dbp1 Has low blood pressure 
dbp2 Has normal blood pressure 
dbp3x Elevated blood pressure 
Relationship  
drel1 In long-standing relationship 
drel2 In new relationship 
drel3 Has no steady relationship 
drel4 No information about relationship  
Children  
dchild1 Is currently breastfeeding 
dchild2 Has children but is not breast-feeding 
dchild3 Has no children 
Fertility plans  
dfut1 Does not want to have children in future 
dfut2 Plans to have children in next 2 years 
dfut3 Plans to have children but not in next 2 years 
dfut4 Unsure about future fertility plans 
Pill preference  
dpil1 Prefers pill to other methods 
dpil2 Has no strong opinion about pill 
dpil3 Prefers methods other than pill 
Weight  concern  
dwt1 Is concerned about gaining weight   
dwt2 Is not concerned about gaining weight 
Compliance  
dcomp1 Has no difficulty with compliance 
dcomp2 Has difficulty with compliance 
Income  
dpay1 Has a low to middle household income 
dpay2 Has a health care card 
dpay3 Has a high household income 
Smoking    
dsmk1 Is a non-smoker 
dsmk2 Smokes less than 10 cigarettes per day 
dsmk3 Smokes 10 or more cigarettes per day 
Key:  The table shows the dummy variables associated with each level of each attribute. Shaded levels represent those that are omitted for 
estimation and so define a particular baseline woman. 
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Table 2: Relative frequencies of contraceptive product consideration and recommendation 
Product Considered Recommended Conversion(%) 
Long acting reversible 
Implant 0.746 0.240 32 
Hormonal IUD 0.564 0.216 38 
Injection 0.549 0.093 17 
IUD 0.251 0.043 17 
Other 
Condom 0.646 0.064 10 
Combined Pill 0.532 0.192 36 
Ring 0.439 0.070 16 
Mini-pill 0.365 0.076 21 
Patch 0.071 0.005  7 
 
 
Table 3: GP Characteristics* 
Characteristic Mean 
Age (years)  47.0 
Female 0.642 
Fellow RACGP 0.605 
Family Planning Certificate 0.327 
Bulk bill all patients 0.278 
Australian graduate 0.759 
Urban practice 0.778 
* Apart from age all other variables are binary dummy variables indicating the presence of the characteristic. In the 
econometric models age is standardized by subtracting the mean of 47 and dividing by two standard deviations. 
 
Table 4: Comparison of distribution of product predictions of being considered:  
Means and range* 
Product Entire Sample Low risk woman Some risk woman  
Long acting reversible 
Implant 0.723 
(0.299, 0.922) 
0.727 
(0.396, 0.898) 
0.705 
(0.357, 0.884) 
Hormonal IUD 0.555 
(0.017, 0.967) 
0.092 
(0.009, 0.261) 
0.285 
(0.045, 0.585) 
Injection 0.527 
(0.153, 0.905) 
0.548 
(0.295, 0.815) 
0.510 
(0.266, 0.791) 
IUD 0.276 
(0.029, 0.708) 
0.166 
(0.069, 0.382) 
0.288 
(0.144, 0.545) 
 
Condom 0.647 
(0.183, 0.896) 
0.668 
(0.308, 0.800) 
0.646 
(0.268, 0.766) 
Combined Pill 0.538 
(0.266, 0.640) 
0.979 
(0.957, 0.993) 
0.454 
(0.266, 0.640) 
Ring 0.437 
(0.095, 0.755) 
0.493 
(0.280, 0.682) 
0.197 
(0.083, 0.323) 
Mini-pill 0.382 
(0.038, 0.858) 
0.168 
(0.055, 0.265) 
0.567 
(0.381, 0.715) 
* Means are provided with (minimum, maximum) underneath. “Entire sample” refers to predictions generated over all 
within sample GP-women combinations. “Low risk woman” considers predictions over all GPs but for a single woman 
defined as the base case attribute levels in Table 1. “Some risk woman” is the baseline women but with the Blood 
pressure attribute set to “Elevated blood pressure” and the Children attribute set to “Breastfeeding”.  
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Figure 1: Stylised example of a choice task completed by doctors  
 
FIRST SCREEN 
Woman Attribute Level 
 Age Aged 30-39 years 
 Reason for encounter Starting prescribed contraception for first time 
 Periods No problem with periods 
 Blood pressure Has low blood pressure 
 Relationship In new relationship 
 Children  Has no children 
 Fertility plans Unsure about future fertility plans 
 Pill preference Has no strong opinion about pill 
 Weight concern Is concerned about gaining weight 
 Compliance Has no difficulty with compliance 
 Income  Has a high income 
 Smoking Is a non-smoker 
   
Choice task Question 1  
What would you discuss? 
Options 
(Check one) 
  ○       Pills only 
  ○       Pills and other methods 
  ●       Other methods but not pills 
   
 
SECOND SCREEN 
Choice task Question 2  
Please select the appropriate set 
of products you would discuss? 
Options  
(Check as many as appropriate) 
  ○      Hormonal  injection  
  ○      Hormonal  implant ○      Vaginal ring 
  ●      Hormonal  IUD ○      Copper IUD 
  ○      Hormonal patch ●      Condoms 
    
 
THIRD SCREEN 
Choice task Question 3  
Which ONE of these would you 
most likely recommend? 
Options 
(Check one) 
 
  ●     Hormonal  IUD ○       Condoms 
    
* Options displayed on the second screen are conditional on the answer to Question 1. The display is as it would appear given 
the answer was “Other methods but not pills”. Thus the Combined Pill and Mini-pill do not appear on the second screen.  If 
instead the GP answered “Pills only” then only the Combined Pill and Mini-pill would appear.  If the GP answered “Pills and other 
methods” then the full list of products would appear. Similarly the choices for Question 3 answered on the third screen were 
restricted to options checked in Question 2. 
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Figure 2: Comparison of model fit: McFadden’s R-squared with a random effects logit as the base  
 
 
 
Figure 3: Estimates of GP scale variability 
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Figure 4: Estimates of patient complexity: Mean effects 
 
 
Figure 5: Estimates of patient complexity: Variance effects 
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Figure 6: The impact of accounting for complexity:  
Comparing Combined Pill predictions from the baseline and general models 
 
 
 
Figure 7: The impact of accounting for complexity:  
Comparing of Implant predictions from the baseline and general models 
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